



HHS Public Access

Author manuscript

Sci Immunol. Author manuscript; available in PMC 2022 October 29.

Published in final edited form as:

Sci Immunol. 2022 April 29; 7(70): eabm8161. doi:10.1126/sciimmunol.abm8161.

Succinate dehydrogenase/complex II is critical for metabolic and epigenetic regulation of T cell proliferation and inflammation

Xuyong Chen¹, Benjamin Sunkel¹, Meng Wang¹, Siwen Kang¹, Tingting Wang¹, JN Rashida Gnanaprakasam¹, Lingling Liu¹, Teresa A. Cassel², David A. Scott³, Ana M. Muñoz-Cabello⁴, Jose Lopez-Barneo⁴, Jun Yang⁵, Andrew N. Lane², Gang Xin⁶, Benjamin Stanton^{1,*}, Teresa W.-M. Fan^{2,*}, Ruoning Wang^{1,*}

¹Center for Childhood Cancer & Blood Diseases, Hematology/Oncology & BMT, Abigail Wexner Research Institute at Nationwide Children's Hospital, The Ohio State University, Columbus, OH, USA.

²Center for Environmental and Systems Biochemistry, Dept. of Toxicology and Cancer Biology, Markey Cancer Center, University of Kentucky, Lexington, KY, USA.

³Cancer Metabolism Core, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.

⁴Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario "Virgen del Rocío"/CSIC/ Universidad de Sevilla, Spain.

⁵Department of Surgery, St Jude Children's Research Hospital, Memphis, TN, USA.

⁶Department of Microbial Infection and Immunity, The Ohio State University, Columbus, OH, USA.

Abstract

Effective T cell-mediated immune responses require the proper allocation of metabolic resources to sustain growth, proliferation, and cytokine production. Epigenetic control of the genome also governs T cell transcriptome and T cell lineage commitment and maintenance. Cellular metabolic programs interact with epigenetic regulation by providing substrates for covalent modifications of chromatin. By employing complementary genetic, epigenetic, and metabolic approaches, we revealed that tricarboxylic acid (TCA) cycle flux fueled biosynthetic processes while controlling the ratio of succinate/ α -ketoglutarate(α -KG) to modulate the activities of dioxygenases that are critical for driving T cell inflammation. In contrast to cancer cells, where succinate dehydrogenase (SDH)/complex II inactivation drives cell transformation and growth, SDH/complex II deficiency in T cells caused proliferation and survival defects when the TCA cycle was truncated, blocking carbon flux to support nucleosides biosynthesis. Replenishing the intracellular nucleoside pool

* Correspondence should be addressed to: **Ruoning Wang**, Phone: 614-335-2980; Fax: 614-722-5895.

ruoning.wang@nationwidechildrens.org; **Teresa W.-M. Fan**, Phone: 858-218-1028, Fax: 859-257-1307. twmfan@gmail.com;

Benjamin Stanton, Phone: 614-355-2691; Fax: 614-722-5895. Benjamin.Stanton@nationwidechildrens.org.

Author contributions: R. Wang conceptualized and supervised this work. X.C. carried out most of the experiments. B.S., B.S., and M.W. performed and analyzed the CD4 T cells ATAC seq and RNA seq data. S.K., T.W., J.R.G., L.L., T.A.C., D.A.S., Y.Y., A.N.L., and G.X. were involved in data collection, analysis, and review. B.S., and T.W.F., provided conceptual input into the study development. A.M.M.C. and J.L.B. provided some experimental animals. X.C., B.S., A.N.L., T.W.F., and R. Wang wrote the manuscript. All authors discussed the results and provided feedback on the manuscript.

Competing interests: All other authors declare no conflict of interest.

partially relieved the dependence of T cells on SDH/complex II for proliferation and survival. SDH deficiency induced a pro-inflammatory gene signature in T cells and promoted T helper 1 and T helper 17 lineage differentiation. An increasing succinate/ α -KG ratio in SDH deficient T cells promoted inflammation by changing the pattern of the transcriptional and chromatin-accessibility signatures and consequentially increasing the expression of the transcription factor, PR domain zinc finger protein 1. Collectively, our studies revealed a role of SDH/complex II in allocating carbon resources for anabolic processes and epigenetic regulation in T cell proliferation and inflammation.

One Sentence Summary

The loss of SDH/complex II function blocks cell proliferation but enhances inflammation in T cells.

Introduction

T cell activation engages glycolysis, the pentose phosphate pathway (PPP), and the tricarboxylic acid (TCA) cycle to prepare T cells for growth, differentiation, and immune defense (1-3). This conversion is reminiscent of the characteristic metabolic switch during the transformation of normal cells to cancer cells (4, 5). In parallel, T cell activation is accompanied by a dynamic remodeling of chromatin accessibility and DNA modifications, which determine the transcriptional status of lineage-specifying genes. Comparative studies reveal epigenetic patterns in accessible, poised, and silenced gene loci in different CD4 subsets (6-8). Mapped permissive and repressive epigenetic modifications in lineage-restricting transcription factors and lineage-specific cytokine genes indicate that such a bivalent epigenetic state is critical for T cell lineage commitment (8-10). As such, a dynamic epigenetic regulation allows progeny cells to maintain lineage-specific transcription programs while retaining some level of plasticity in response to environmental cues. Also, central carbon metabolism allocates carbon inputs to metabolites that are substrates, antagonists, and cofactors of epigenetic-modifying enzymes. Thus, central carbon metabolism is instrumental in establishing and maintaining the epigenetic landscape for cell fate determination. However, how and which metabolic pathways control the epigenome for the proliferation and differentiation of T_H1 cells still remains elusive.

While an essential function of the TCA cycle is to sustain the oxidative carbon flux to meet energy consumption needs, the TCA cycle also coordinates the carbon input (anaplerosis) and carbon output (cataplerosis) to ensure biosynthetic activities and epigenetic regulation (11-13). Specifically, α -ketoglutarate (α -KG), an intermediate of the TCA cycle, is an essential co-substrate of α -KG dependent dioxygenases such as specific histone and DNA demethylases. In contrast, succinate and fumarate are potent inhibitors of these enzymes (14). Therefore, the ratio changes of these metabolites can impact gene transcription through epigenetic mechanisms (15-17). Succinate dehydrogenase (SDH)/complex II consists of four subunits (SDHA-D) that function in both the TCA cycle and the electron transportation chain (ETC). Its enzymatic activities that convert succinate to fumarate are coupled with reducing FAD to FADH₂ and transferring an electron (complex II) into the ETC. Thus, SDH-dependent metabolic reaction represents a critical branch point in the TCA cycle. SDH is

also a tumor-suppressor since inactivating SDH subunits leads to a spectrum of hereditary tumors, suggesting that inactivating this enzyme can confer survival and proliferation advantages to tumor cells (18, 19).

As activated T cells share metabolic characteristics with tumor cells (1, 20), we sought to investigate the role of SDH in T cells. Here, we reported that the TCA cycle enzyme SDH was indispensable for driving T cell proliferation by funneling carbon to support anabolic processes. In addition, the TCA cycle flux was constricted based on the availability of succinate that promotes the expression of pro-inflammatory genes through changing the T cell epigenome. Our findings implicated a role of the SDH/complex II in coupling the central carbon metabolism to epigenetic regulation to regulate T cell proliferation and inflammation coordinately.

Results

SDHB is required for T cell proliferation and survival

Loss-of-function mutations in SDH lead to a spectrum of hereditary tumors, suggesting that the resulting truncated TCA cycle can confer survival and proliferation advantages to tumor cells (18, 19). Active T cells share metabolic characteristics with tumor cells and, therefore, may survive and proliferate in the absence of SDH activities (21). The critical functions of the TCA cycle include producing energy through coupling with the oxidative phosphorylation and generating biosynthetic precursors through cataplerosis (11). Accordingly, activated T cells could rapidly incorporate glucose- and glutamine-derived carbons into the TCA cycle metabolites and amino acids, indicating a robust TCA cycle coupled with anaplerosis and cataplerosis (Fig. S1A-C). SDH inhibitors with distinct modes of inhibition (22, 23) significantly suppressed proliferation and decreased cell viabilities after T cells activation (Fig. S2A-D). To further illustrate the role of SDH in T cells, we generated a T cell-specific *SDHB* knockout mouse strain (*SDHB* cKO) by crossing the *SDHB^{fl}* mouse strain with the CD4-Cre mouse strain. qPCR and immune blot (IB) analyses validated the deletion of SDHB (Fig. 1A), and SDH ablation resulted in a partially truncated TCA cycle, as evidenced by the accumulation of succinate and reduction of fumarate (Fig. 1B). While SDHB deletion did not result in any defects in T cell development in the thymus, it did reduce the percentage of T cells, particularly CD8 T cells, in the spleen and lymph node (Fig. S3A). In addition, the percentage of naturally occurring interferon- γ (IFN- γ) producing, interleukin-17 (IL-17) producing, and Foxp3⁺ CD4⁺ T cells were comparable in both wild-type (WT) and *SDHB* cKO mice (Fig. S3B). SDHB deletion in T cells significantly delayed cell cycle progression from G0/1 to S phase (Fig. 1C), suppressed proliferation (Fig. 1D), induced more cell death and reduced cell numbers (Fig. 1E-F, S3C), which were associated with moderately reduced cell surface activation markers (Fig. S3D), cell size (Fig. S3E), and protein content (Fig. S3F).

To assess the impact of ablating SDHB on CD4⁺ T cells *in vivo*, we first employed a well-established competitive homeostatic proliferation assay to determine the ratio and carboxyfluorescein succinimidyl ester (CFSE) dilution pattern of purified WT (*Thy1.1⁺*) or *SDHB* cKO (*Thy1.2⁺*) CD4⁺ T cells in a lymphopenic host (*Rag^{-/-}*). Both the ratio between wild type (WT) and *SDHB* cKO CD4⁺ T cells and CFSE dilution patterns suggested that

the loss of SDHB dampens T cell proliferation *in vivo* (Fig. 1G, S3G and S4A). Next, we measured antigen-specific, TCR-dependent proliferation of WT or *SDHB* cKO CD4⁺ T cells. We crossed *Thy1.1* and CD4-Cre, *SDHB*^{fl} mice with OT-II transgenic mice to generate WT (*Thy1.1*⁺) and *SDHB* cKO (*Thy1.2*⁺) donor OT-II strains in CD45.2⁺ background. We then adoptively transferred CFSE labeled WT and *SDHB* cKO CD4⁺ T cell into CD45.1⁺ mice immunized with chicken ovalbumin (OVA₃₂₃₋₃₃₉). Consistent with the homeostatic proliferation results, *SDHB* cKO OT-II specific CD4⁺ T cells displayed a significant proliferation defect in an antigen-specific manner after immunization (Fig. 1H, S3H and S4B). Experimental autoimmune encephalomyelitis (EAE), an inflammatory demyelinating disease model, is induced by active immunization with myelin-oligodendrocyte-glycoprotein (MOG) (Fig. 1I). We used this well-characterized system to investigate the *in vivo* CD4⁺ T cell response in *SDHB* cKO mice. In line with our homeostatic and antigen-specific proliferation results, the genetic deletion of SDHB in T cells protected the pathogenic progression of mice (Fig. 1I) and dramatically reduced leukocyte infiltration (Fig. 1J), indicating that the dominant phenotype of SDH-deficient T cells in this model was the proliferation defect. Collectively, these findings suggested that ablating SDH/complex II activities significantly dampened T cell proliferation and *survival in vitro* and *in vivo*.

SDH inactivation decouples the TCA cycle from nucleoside biosynthesis

While an essential function of the TCA cycle is to sustain the oxidative carbon flux to meet energy consumption needs, the metabolic flux via the TCA cycle is also critical for carbon allocation, ensuring that biosynthetic precursors production is coupled with nutrient catabolism (11-12). Activated *SDHB* cKO T cells consistently displayed lower catabolic activities, such as glycolysis, pentose phosphate pathway (PPP), glutamine oxidation, but not fatty acid oxidation (FAO) as compared with WT active T cells (Fig. 2A-D). Since glutamine is a major carbon source for replenishing the TCA cycle intermediate metabolite α -ketoglutarate (α -kg) in T cells after activation (24), we supplied ¹³C₅-glutamine as a metabolic tracer in T cell culture media and followed ¹³C incorporation into downstream metabolites in T cells after activation. The ¹³C₄ isotopologue of succinate was accumulated, but the corresponding ¹³C₄ or ³C₃ isotopologues of downstream metabolites including fumarate, malate, aspartate, and pyrimidine nucleotides were significantly reduced in activated *SDHB* cKO T cells as compared with activated WT T cells (Fig. 2E). SDHB deficiency reduced the level of intracellular aspartate (Fig. 2E), which is produced from the TCA cycle metabolite (oxaloacetate) and consequently utilized for nucleotide and DNA/RNA biosynthesis (11-12). Notably, the incorporation of carbon from ¹⁴C-glutamine into RNA and DNA was significantly suppressed in activated *SDHB* cKO T cells as compared with activated WT T cells (Fig. 2F). Metabolite profiling also revealed a global decrease of intracellular pyrimidine nucleotides, purine nucleotides, and their precursors in activated *SDHB* cKO T cells (Fig. 2G). Finally, the overall DNA/RNA content was lower in *SDHB* cKO T cells than WT T cells after activation (Fig. 2H). Collectively, our metabolic experiments have shown that the carbon flux from glutamine to the TCA cycle intermediate metabolites, nucleotides and DNA/RNA biosynthesis was dampened in the absence of SDH/complex II activity.

Nucleosides supplementation partially compensates for the loss of de novo biosynthesis of nucleotides in *SDHB* cKO T cells

We then sought to determine the importance of SDH in directing TCA cycle carbon flow to nucleotide biosynthesis for supporting T cell proliferation. Since cells could directly utilize nucleosides through salvage pathway, we reasoned that providing nucleosides could bypass the block in de novo synthesis and consequently overcome some of the T cell defects caused by *SDHB* deficiency. Indeed, supplementation with a mixture of nucleosides (adenosine, uridine, guanosine, thymidine, cytidine, inosine) partially restored the viability and proliferation of *SDHB* cKO T cells after activation (Fig. 3A-D), which was accompanied by partial restoration of DNA/RNA content (Fig. 3E) and promoted cell cycle progression from G0/1 to S phase (Fig. 3F). Nucleosides supplement did not affect WT cells growth and proliferation (Fig. 3A-D). In addition, adding inosine together with pyrimidines (thymidine, cytidine, and uridine) maximized the rescue effect (Fig. 3G-J), demonstrating the importance of SDH in supporting both purine and pyrimidine biosynthesis.

Nucleotide pool imbalance can cause DNA damage and, consequently, induce apoptosis (25). In support of this concept, *SDHB* deletion led to high levels of DNA damage marker (phosphor-histone H2AX), and nucleosides supplementation reversed this effect (Fig. S5A-B). Accordingly, the pan-caspase inhibitor (QVD) enhanced the cell viability but not the proliferation of *SDHB* cKO T cells (Fig. S5C-E). The combination of nucleosides supplementation and QVD further enhanced the viability but not the proliferation of *SDHB* cKO T cells (Fig. S5C-E). A defective SDH/complex II can increase ROS production (26). However, we only observed a moderate induction of mitochondrial ROS in *SDHB* cKO T cells (Fig. S5F). ROS scavengers failed to rescue cell viability and proliferation defects in *SDHB* cKO T cells (Fig. S5G-I).

To ensure no phenotypic discrepancies between genetic modulation of different subunits of SDH in T cells, we generated a T cell-specific *SDHD* knockout strain (*SDHD* cKO) by crossing CD4-Cre mice with previously reported *SDHD*^{fl} mice (27). Similar to the effect of *SDHB* deletion in T cells, *SDHD* deletion reduced the percentage of T cells in the spleen and lymph node without causing defects in T cell development in the thymus (Fig. S6A-B). *SDHD* deletion significantly suppressed proliferation and caused more death after T cells activation, which could be partially reversed by nucleosides supplementation (Fig. S6C-F). Next, we examined the effect of SDH deficiency on T cell survival and proliferation under polarization conditions. Both *SDHB* and *SDHD* deficiency resulted in cell survival and proliferation defects in T helper 1 (T_H1) (Fig. S7 A-B) and T helper 17 (T_H17) (Fig. S7 C-D) polarization conditions. Together, our data suggested that a crucial role of the TCA cycle in supporting T cell proliferation was to allocate carbon for nucleotides biosynthesis (Fig. S7E).

SDH inactivation results in a pro-inflammatory gene signature in T cells after activation

To gain more mechanistic insights into the effects of *SDHB* deletion on T cells, we performed RNA-seq in activated WT and *SDHB* cKO T cells, which revealed an enriched pro-inflammatory gene signature in *SDHB* cKO T cells after activation (Fig. 4A-C). Active *SDHB* cKO T cells, but not naïve, expressed higher levels of four representative pro-

inflammatory genes, including *Il17a*, *Il17f*, *Ifng*, and *Il22*, than WT T cells, indicating that TCR activation is required to achieve an enriched pro-inflammatory gene signature in *SDHB* cKO T cells (Fig. 4D). Consistent with gene expression data, the culture media collected from *SDHB* cKO T cells contained significantly higher levels of pro-inflammatory cytokines than the culture media collected from WT T cells (Fig. S8A). Nucleosides supplementation, which could partially rescue cell proliferation and survival (Fig. 3A-D), failed to reduce the pro-inflammatory cytokine expression in *SDHB* cKO T cells (Fig. 4E). Also, the culture media collected from *SDHB* cKO T cells could not increase pro-inflammatory gene expression in WT T cells (Fig. 4F). Thus, a cell-intrinsic mechanism that is unrelated to changes in proliferation and survival or secretory molecules was responsible for the pro-inflammatory gene signature in *SDHB* cKO T cells after activation.

The increasing intracellular succinate/ α -KG ratio promotes the expression of pro-inflammatory genes in *SDHB* cKO T cells after activation

SDHB deficiency reciprocally increased the level of succinate while reducing α -KG in T cells after activation (Fig. S8B). Such an increased succinate/ α -KG ratio suppressed the enzymatic activities of the dioxygenase family, impacting the hypoxia signaling response and DNA/histone methylation pattern (Fig. 5A), both of which may lead to a pro-inflammatory response (28-30). Correspondingly, cell-permeable succinate (22) increased succinate/ α -KG ratio (Fig. S8C) and partially mimicked the effect of *SDHB*-deficiency on upregulating pro-inflammatory genes in WT T cells after activation (Fig. 5B). Conversely, cell-permeable α -KG (dimethyl- α -KG) decreased the succinate/ α -KG ratio (Fig. S8C) and reduced the level of pro-inflammatory genes in *SDHB* cKO T cells after activation (Fig. 5C). Similarly, a glutamate dehydrogenase inhibitor (R162), which could reduce glutamine-derived anaplerotic flux to attenuate succinate buildup, decreased the expression of pro-inflammatory genes in *SDHB* cKO T cells after activation (Fig. 5D). Finally, *SDHD* deficiency phenocopied *SDHB* deficiency in inducing pro-inflammatory gene expression, which was reversed by cell-permeable α -KG (Fig. S8D).

Next, accessed the effects of changing the succinate/ α -KG ratio on CD4⁺ T cell differentiation. The succinate/ α -KG ratio in proinflammatory T cell lineages (T_H1 and T_H17) was higher than either uncommitted lineage (T_H0) or anti-inflammatory lineage (iT_{reg}) (Fig. S8E), indicating that increasing the succinate/ α -KG ratio might promote T_H1 and T_H17 differentiation. Indeed, cell-permeable succinate enhanced pro-inflammatory T_H1 and T_H17 cell differentiation, which could be reversed by cell-permeable α -KG (Fig. 5E-F). Similarly, cell-permeable 2-hydroxyglutarate (L-octyl-L2HG) that increased intracellular 2-HG levels to antagonize α -KG dependent dioxygenases (31) enhanced T_H1 and T_H17 differentiation. Cell-permeable α -KG could partially reverse the effect of 2-HG on T cell differentiation (Fig. S9A-B). *SDHB* cKO T cells failed to proliferate and could not generate IFN- γ ⁺ CD4⁺ T cells under T_H1 polarization conditions or IL-17⁺ CD4⁺ T cells under T_H17 polarization conditions (Fig. S9C). These results are in line with previous observations that cell proliferation is required to achieve optimized T cell polarization (32). Genomic deletion and RNA depletion of *SDHB* require a specific time after Cre activation. Also, the protein half-life of *SDHB* is around 10 hrs (33). We envisioned that a tamoxifen-inducible Cre recombinase (CreERT2) model might allow us to bypass the effect

of SDHB deficiency on T cell activation and proliferation if Cre functions during activation. Compared with WT cells, acute deletion of SDHB largely bypassed its requirement for driving cell proliferation but enhanced T_H1 and T_H17 differentiation (Fig. S9D-E). Cell-permeable α -KG eliminated the effects of acutely deleting SDHB on T cell differentiation (Fig. S9D-E). Using CreERT2 model, we have differentiated the role of SDH in regulating T cell activation and proliferation from its role in driving T cell differentiation. Together, our results suggested that increasing the succinate/ α -KG ratio promoted pro-inflammatory gene expression and enhanced T_H1 and T_H17 differentiation *in vitro*.

HIF1- α is dispensable for enhanced pro-inflammatory gene signature in *SDHB* cKO T cells

An increased succinate/ α -KG ratio suppressed enzymatic activities of the α -KG -dependent dioxygenases, which include prolyl hydroxylases, Ten-eleven translocation (TET) enzymes, and lysine demethylases, and may consequently impact inflammation via HIF-1 α and/or epigenetic mechanism (Fig. 5A) (34, 35). HIF1- α plays a role in enhancing inflammation in T cells and other immune cells (36-38). To determine if HIF1- α is responsible for upregulating pro-inflammatory genes, we generated a T cell-specific *SDHB* and *HIF1- α* double knockout (dKO) strain by crossing the *HIF1- α ^{fl}* with CD4-Cre, *SDHB^{fl}* strain. *HIF1- α /*SDHB* dKO T cells displayed comparable phenotypes in T cell development, cell survival and proliferation compared with *SDHB* cKO T cells after activation (Fig. S10A-F). Pro-inflammatory gene expression was not reduced in *HIF1- α /*SDHB* dKO T cells compared to *SDHB* cKO T cells after activation (Fig. S10G). Conversely, cell-permeable succinate could enhance T_H1 and T_H17 cell differentiation in a HIF1- α independent manner (Fig. S11A-B). Collectively, our results suggested that HIF1- α did not mediate pro-inflammatory phenotypes in *SDHB* cKO T cells after activation.**

SDHB deficiency promotes a pro-inflammatory gene signature through regulating chromatin accessibility and pro-inflammatory transcription factors

Next, we measured succinate, α -KG, DNA, and histone methylation levels in WT and *SDHB* cKO naïve T cells. Compared with the WT T cells, the *SDHB* cKO naïve T cells contained a higher level of succinate but not α -KG than WT T cells (Fig. S12A). In contrast to control T cells, the *SDHB* and *SDHD* cKO T cells or T cells treated with cell-permeable succinate displayed higher levels of 5-methylcytosine (5-mC) and histone methylations in several key lysine residues that are often associated with transcriptional activities (39, 40) (Fig. S12 B-F). We reasoned that the DNA and histone methylations might work in concert to reprogram an epigenetic state via modulating chromatin accessibility, consequently leading to induction of inflammatory genes in activated T cells with succinate accumulation. To test this hypothesis, we examined the genome-wide transcriptomes and chromatin-accessibility by performing RNAseq and Assay for Transposase Accessible Chromatin with high-throughput sequencing (ATAC-seq) in parallel in activated CD4⁺ WT and *SDHB* cKO T cells. Indeed, ATAC-seq revealed distinctive patterns of DNA accessibility that were associated with genomic loci of genes involved in T cell activation and inflammation in activated WT and *SDHB* cKO CD4⁺ T cells (Fig. 6A-B). After integrating the RNA-seq and ATAC-seq data, we found that the induction of pro-inflammatory genes and transcription factors known to regulate T cell differentiation and inflammation were concordant with the increase in chromatin accessibility of these genes in the activated *SDHB* cKO CD4⁺ T cells

(Fig. 6C). PR domain zinc finger protein 1 (*Prdm1*) was among these genes with increased transcript and DNA accessibility. *Prdm1* encodes B-lymphocyte-induced maturation protein (Blimp-1), a transcription factor known which is co-localized with STAT-3, p300, ROR γ t on the *Il23r*, *Il17f*, and *Csf2* cytokine loci to regulate T cell differentiation and inflammation (41, 42). Analysis of transcriptional factor binding motifs in the differential accessibility regions revealed that *Prdm1* was one of the top transcription factors that may gain increased chromatin accessibility at the regulatory elements of the T cell activation and inflammation genes in the activated *SDHB* cKO CD4⁺ T cells (Fig. 6D). In addition, ATAC-seq analysis of T cells of WT and *SDHB* cKO under naïve conditions also showed a significant motif enrichment of *Prdm1* in the differential accessibility regions, portending the increased transcription of its target gene upon stimulation (Fig. S12G-H). We, therefore, hypothesized that transcription factors, such as *Prdm1* that showed concordant increases in both their expression level and DNA accessibility, may play a key role in driving inflammation in *SDHB* cKO CD4⁺ T cells. Among a panel of transcription factors that displayed enhanced DNA accessibility in either activated or naïve *SDHB* cKO CD4⁺ T cells (Fig. 6D and S12G), *Prdm1*'s expression was enhanced by cell-permeable succinate and *SDHB* deletion (Fig. 6E-G). Moreover, cell-permeable α -KG reduced the expression of *Prdm1* in *SDHB* cKO CD4⁺ T cells (Fig. 6E-F).

Next, we employed a CRISPR-Cas9 approach to testing if *Prdm1* was required for regulating the expression of inflammatory genes and T cell differentiation in the context of *SDHB* deletion and succinate accumulation. Indeed, the deletion of *Prdm1* reduced the level of pro-inflammatory genes *Il17a*, *Il17f*, *Ifng*, but not *Il22* in *SDHB* cKO T cells (Fig. 7A-B). Moreover, deletion of *Prdm1* eliminated the effect of cell-permeable succinate on promoting T_H1 and T_H17 differentiation (Fig. 7C-D). Collectively, these results suggested that TCA cycle metabolites (succinate/ α -KG) regulated T cell inflammation through a coordinated epigenetic and transcriptional control of inflammatory genes.

Changing the succinate/ α -KG ratio regulates *Prdm1*/Blimp-1 expression and T cell differentiation through an epigenetic mechanism

Next, we assessed the effect of modulating the succinate/ α -KG ratio on *Prdm1*/Blimp-1 expression and T cell differentiation. Cell-permeable α -KG moderately reduced *Prdm1*/Blimp-1 expression under T_H1 and T_H17 polarization conditions (Fig. S13A-B). Similarly, treating T cells with a competitive inhibitor of SDH (NV161) (22, 43) in a dose without significantly compromising cell proliferation (Fig. S13C) enhanced T_H1 and T_H17 differentiation and *Prdm1*/Blimp-1 expression (Fig. S13D-G). In line with the effect of acutely deleting *SDHB* on T cell differentiation (Fig. S9D-E), acutely deleting *SDHB* increased *Prdm1*/Blimp-1 expression under T_H1 and T_H17 polarization conditions, which could be reversed by cell-permeable α -KG (Fig. S13H-I). We reasoned that H3K4me3 might play a role in regulating *Prdm1*. Indeed, chromatin immunoprecipitation (ChIP)-qPCR revealed that the H3K4me3 signal was higher in *SDHB* cKO than WT CD4⁺ T cells (Fig. S14A). The state of H3K4me3 is determined by the lysine-specific demethylase 5 (KDM5) family and the histone methyltransferase, mixed-lineage leukemia 1 (MLL1) (44, 45). Inhibiting KDM5 by C70 (46) increased the level of H3K4me3, accompanied by increased expression of *Prdm1* in WT CD4⁺ T cells following activation (Fig. S14 B-D).

Conversely, inhibiting MLL1 by MM102 (47) reduced the level of H3K4me3 and the expression of *Prdm1* in *SDHB* cKO CD4⁺ T cells (Fig. S14B and S14E-F). Moreover, inhibiting KDM5 by C70 increased the level of H3K4me3 under T_H1 and T_H17 polarization conditions, accompanied by enhanced differentiation (Fig. S14G-J). Conversely, inhibiting MLL1 by MM102 reversed the effects of acutely deleting *SDHB* on H3K4me3 during T_H1 and T_H17 differentiation (Fig. S15A-H). Together, these results indicated that changing the succinate/ α -KG ratio might regulate *Prdm1* expression and T cell differentiation through modulating the level of H3K4me3.

Discussion

We revealed a critical role of SDH/complex II in allocating carbon resources for anabolic processes and epigenetic regulation in T cell proliferation and inflammation. Rapidly evolving pathogens impose selective pressures on host immune cells' metabolic fitness and metabolic plasticity, allowing immune cells to maintain homeostasis while remaining ready to mount rapid responses under diverse metabolic and immune conditions (48-51). Beyond this, the availability of specific metabolites and the pathways that process them interconnect with signaling events and epigenetic regulators in the cell, orchestrating metabolic checkpoints that influence T cell activation, differentiation, and immune function (1-3, 52-57). While the essential function of the TCA cycle is to sustain the oxidative carbon flux to meet energy consumption needs, the metabolic flux via the TCA cycle is also critical for carbon anabolism, ensuring that production of biosynthetic precursors of protein, lipids, and DNA/RNA is coupled with energy production from nutrients to sustain cell growth. Accordingly, the major role of the ETC in supporting cell proliferation is to regenerate nicotinamide adenine dinucleotide (NAD)⁺ and to permit aspartate synthesis in cancer cells (55, 58-60). Similarly, we found that carbon input (mainly through glutamine) to replenish TCA cycle intermediates (anaplerosis) was balanced with an output of 4-carbon intermediates from the TCA cycle to aspartate and nucleosides and nucleotides (cataplerosis) in T cells. These results suggest that active T cells share metabolic characteristics with tumor cells (1, 20).

Unlike hyper-proliferative tumor cells, where inactivating the TCA cycle enzymes SDH can confer survival and proliferation advantages to tumor cells (18, 19), we found that SDH-dependent steps were vital for carbon allocation via the TCA cycle in supporting anabolic processes to drive T cell proliferation. The additional genetic alterations may confer a high degree of metabolic adaptation to SDH/complex II deficient cancer cells (61, 62). Inhibiting SDH suppresses T-cell inflammation and macrophages (21, 63, 64). In contrast, we found that increasing the succinate/ α -KG ratio by inhibiting SDH or providing cell-permeable metabolites promoted T cell inflammation and differentiation. Since different approaches, materials, and cell types were used and studied across our studies and previous studies, we reasoned that the combination of multiple factors, including differences in pharmacological reagents, genetic approaches, cellular and biological contexts, caused the discrepancies between our findings and previous findings.

Succinate is necessary to promote inflammation during macrophage activation (65, 66). Endogenous metabolite itaconate regulates inflammatory cytokine production during

macrophage activation by targeting SDH/complex II, implicating metabolites as key regulation signals (63, 67, 68). In macrophages, succinate exerts its pro-inflammatory actions through a plethora of mechanisms, including stabilizing HIF-1 α , affecting mitochondrial ROS (mtROS) production, and activating cell surface receptor, the G-protein coupled receptor succinate receptor 1 (SUCNR1) (36, 63, 69, 70). In T cells, the TCA cycle allocates carbon inputs to modulate substrates, antagonists, and cofactors of epigenetic-modifying enzymes, thereby enacting epigenetic changes during T cell activation (15-17). Particularly, succinate is a critical metabolite regulator of histone and DNA demethylases (12, 15-17). We found that the succinate/ α -KG ratio in proinflammatory T cell lineages (T_H1 and T_H17) was higher than either uncommitted lineage (T_H0) or anti-inflammatory lineage (iT_{reg}), indicating that a higher succinate/ α -KG ratio might be required for the differentiation of proinflammatory T cell lineages.

T cell activation is accompanied by a dynamic remodeling of chromatin, accessibility, and histone modifications, which determine the transcriptional signatures of lineage-specifying genes via cell type-specific gene regulatory elements. The epigenetic landscape promotes the faithful execution of lineage-restricting transcription programs while maintaining a degree of plasticity in response to intracellular and environmental cues (9, 10). Mitochondrial complex III regulates T cell activation and regulatory T cell functions through controlling mitochondria ROS and DNA methylation, respectively (1, 71). We uncovered distinctive patterns of DNA accessibility that were associated with genomic loci of inflammatory genes and transcription factors that regulate inflammatory genes in WT and *SDHB* cKO CD4⁺ T cells.

We observed a concordant increase in the expression and the motif accessibility of transcription factor *Prdm1*, a known regulator of T cell differentiation and inflammation, in *SDHB* cKO CD4⁺ T cells compared to WT CD4⁺ T cell (41). Succinate accumulation may have induced *Prdm1* expression via an H3K4me3-dependent mechanism. Moreover, deletion of *Prdm1* eliminated the effect of succinate on promoting the expression of the inflammatory genes and effector T cell differentiation. However, epigenetic regulation of multiple other genes was also involved in mediating the effect of succinate in promoting T cell inflammation. In addition to *prdm1*, several other transcription factors known to regulate T cell differentiation and inflammation also displayed enhanced DNA accessibility and expression in the activated *SDHB* cKO CD4 T cells. These results supported the idea that SDH/complex II was necessary for promoting T cell inflammation through a coordinated epigenetic and transcriptional control of inflammatory genes.

Collectively, TCA cycle flux and the ETC may act concertedly to ensure coordinated carbon assimilation, energy production, and epigenetic regulation. The participation of the master transcription factor such as *Prdm1* in such combinational context adds one layer of regulatory flexibility on cells, permitting contextual gene expression patterns. This mechanism in T cells may provide some insights to explain how metabolic constraints impose on the epigenetic and transcriptional regulation of a broad range of cell-fate transitions.

Materials and Methods.

Study design

This study investigates the function of Complex II/SDH in T cells. We assessed the T cell survival, activation, proliferation, differentiation, and inflammation in the context of inhibiting or enhancing SDH activities through a combination of genetic, pharmacological, and metabolic approaches. For each experiment, n values and the number of experimental replicates are specified in corresponding figure captions. In murine experiments, males and females were used in equal proportions.

Mice

Mice with one targeted allele of *SDHB* on the C57BL/6 background (*SDHB*^{tm1a(EUCOMM)Hmgu}) were generated by The European Conditional Mouse Mutagenesis Program (EUCOMM) (72). The mice were first crossed with a transgenic Flippase strain (B6.129S4 *Gt(ROSA)26Sor^{tm1(FLP1)Dym}/RainJ*) to remove the LacZ-reporter allele and then crossed with the CD4-Cre strain to generate T cell-specific *SDHB* knockout strain (*SDHB* cKO). *SDHB*^{fl} were crossed with ROSA26CreERT2 to generate the acute deletion model. Mice with one targeted allele of *SDHD* on the C57BL/6 background were crossed with the CD4-Cre strain to generate the CD4Cre *SDHD* cKO mice (*SDHD* cKO) (27). *SDHB*^{fl} were crossed with CD4Cre *HIF1-α* KO mice (73) to generate T cell-specific *SDHB* and *HIF1-α* double knockout (dKO) strain. OT-II mice (B6.Cg-Tg(TcraTcrb)425Cbn/J) were crossed with CD4Cre *SDHB* cKO mice to generate the OT- II CD4Cre *SDHB* cKO mice. OT-II mice (B6.Cg-Tg(TcraTcrb)425Cbn/J) were crossed with *Thy1.1*⁺ mice (B6.PL-*Thy1a*/CyJ) to generate OT-II *Thy1.1* mice. C57BL/6 (WT) mice, CD45.1⁺ mice (B6.SJL-Ptprca Pepcb/BoyJ), and Rag1^{-/-} mice (B6.129S7-Rag1tm1Mom/J) were obtained from the Jackson Laboratory (JAX, Bar Harbor, ME). Mice with gender and age-matched (7-12 weeks old) were used in the experiments. All mice were bred and kept in specific pathogen-free conditions at the Animal Center of Abigail Wexner Research Institute at Nationwide Children's Hospital. Animal protocols were approved by the Institutional Animal Care and Use Committee of the Abigail Wexner Research Institute at Nationwide Children's Hospital (IACUC; protocol number AR13-00055).

Mouse T cell isolation and culture

Total CD3⁺ T cells or naïve CD4⁺ T cells were enriched from mouse spleen and lymph nodes by negative selection using MojoSort Mouse CD3 T Cell Isolation Kit or MojoSort Mouse CD4 Naive T Cell Isolation Kit (MojoSort, Biolegend). Isolated T cells (1×10⁶ cells/mL) were maintained in culture media containing mouse IL-7 (5 ng/mL) for naïve condition or stimulated with mouse IL-2 (100 U/mL) as well as plate-bound anti-mCD3 and anti-mCD28 antibodies for activation condition. Culture plates were pre-coated with 2 µg/mL anti-mCD3 (clone 145-2C11, Bio X Cell) and 2 µg/mL anti-mCD28 (clone 37.51, Bio X Cell) antibodies overnight at 4°C. For T cell's CFSE dilution analysis, 1-2 × 10⁷ cells were incubated in 4 µM PBS-diluted CFSE (Invitrogen) for 10 min; cells were then washed three times with RPMI-1640 medium containing 10% FBS for culture.

For CD4⁺ T cell differentiation, freshly isolated naïve CD4⁺ T cells ($0.6 \times 10^6/\text{mL}$) were stimulated with plate-bound antibodies and with mIL-2 (200 U/mL), mIL-12 (5 ng/mL, PeproTech) for T_H1 differentiation, with mIL-6 (50 ng/mL, PeproTech), hTGF- β 1 (2 ng/mL), anti-mIL-2 (8 $\mu\text{g}/\text{mL}$, Bio X Cell), anti-mIL-4 (8 $\mu\text{g}/\text{mL}$, Bio X Cell), and anti-mIFN- γ (8 $\mu\text{g}/\text{mL}$, Bio X Cell) for T_H17 differentiation, or with mIL-2 (200 U/mL) and hTGF- β 1 (5 ng/mL, PeproTech) for iTreg differentiation. Of note, 48 wells culture plates were pre-coated with 5 $\mu\text{g}/\text{mL}$ anti-mCD3 (clone 145-2C11, Bio X Cell) and 5 $\mu\text{g}/\text{mL}$ anti-mCD28 (clone 37.51, Bio X Cell) antibodies over night at 4°C for T_H1 and iTreg polarization or were pre-coated with 10 $\mu\text{g}/\text{mL}$ anti-mCD3 (clone 145-2C11, Bio X Cell) and 10 $\mu\text{g}/\text{mL}$ anti-mCD28 (clone 37.51, Bio X Cell) antibodies over night at 4°C for T_H17 polarization. At day 3, eBioscience™ Cell Stimulation Cocktail of phorbol 12-myristate 13-acetate (PMA), ionomycin, brefeldin A and monensin (eBioscience) were added into T_H1 or T_H17 cells for 4 h followed by intracellular detection of cytokines.

All cells were cultured in RPMI 1640 media supplemented with 10% (v/v) heat-inactivated dialyzed fetal bovine serum (DFBS), 2 mM L-glutamine, 0.05 mM 2-mercaptoethanol, 100 units/mL penicillin and 100 $\mu\text{g}/\text{mL}$ streptomycin at 37°C in 5% CO₂. Single nucleosides (NS) including Adenosine (A), Uridine (U), Inosine (I), Cytidine (C), Guanosine (G), Thymidine (T) were diluted in water and mixed to reach a final concentration of 300 μM NS mixture, 200 μM TCUI combination or 150 μM TCU combination (50 μM for each), Atpenin A5 (A5, 100nM), diacetoxymethyl malonate (NV161, 50-100 μM), dimethyl-itaconate (DI, 0.5mM), or 4-octyl-itaconate (4OI, 500 μM), 20uM QVD-OPh, 1mM NAC, 1mM GSH EE, 100 μM or 25 μM NV118, 10mM or 2mM dimethyl α -ketoglutarate (α -KG), 1 μM L(S)-2HG, 50 μM R162, 600nM 4OHT, 10-25 μM MM102, or 5-10 μM KDM5-C70 were used in the indicated experiments. All reagents, including cytokines, antibodies, inhibitors, and chemicals, are listed in supplemental table 1.

Flow Cytometry

For analysis of surface markers, cells were suspended in phosphate-buffered saline (PBS) containing 2% (w/v) bovine serum albumin (BSA) and incubated with antibodies (supplemental Table 2) for 30 min at 4°C. Cells were washed and stained with 7AAD (Biolegend) for cell viability analysis for 5 min before running on a flow cytometer. For intracellular staining, cells were collected and stained with surface markers first. Then cells were stimulated with (for cytokines staining) or without (for non-cytokine proteins staining) stimulation cocktails followed by fixation and permeabilization using FoxP3 Fixation/Permeabilization Kit (eBioscience) and staining of intracellular proteins. For DNA methylation assay, cells were harvested, washed with PBS, and fixed with 4% paraformaldehyde for 15 min at room temperature. After washing with PBS, cells were permeabilized by 0.5% Triton X-100 in PBS for 15 min at room temperature, then incubated in 2 N HCl for 30 min at 37°C. Then, cells were neutralized with 100 mM Tris HCl pH 8.8 for 10 min followed by extensive washes with 0.05% Tween 20 in PBS and blocking in 1% BSA and 0.05% Tween 20 in PBS for 2 h. Cells were incubated with the anti-5-methylcytosine (5-mC) antibody for 1 h, followed by 7AAD staining for 5 min for DNA content analysis (74). For histone methylations assay, cells were collected and stained with surface markers, then were fixed and permeabilized using the FoxP3 Fixation/

Permeabilization Kit (eBioscience). Cells were incubated with a primary monoclonal antibody for 1 h at room temperature, washed with staining buffer, and incubated with a secondary antibody (Alexa-Fluor 647- or Alexa-Fluor 405-conjugated goat anti-mouse Ig antibodies; Invitrogen, France) for 45 min at room temperature. Histone methylation levels were normalized to the level of total H3. Flow cytometry antibodies are listed in supplemental Table 2. For DNA/RNA content assay, cells were collected and stained with surface markers, then were fixed with 4% paraformaldehyde for 30 min at 4°C and permeabilized with FoxP3 permeabilization solution (eBioscience). Cells were stained with 7AAD for 5 minutes and then stained with pyronin-Y (4µg/ml, PE) for 30 minutes. Cells were washed and then analyzed by flow cytometer using PE channel for pyronin-Y and PerCP channel for 7AAD. Protein synthesis assay kit (Item No.601100, Cayman) was used for protein content assay. Cells were incubated in O-propargyl-puromycin (OPP) for 1 h, then were fixed and stained with 5 FAM-Azide. Cells were then washed and analyzed by flow cytometer using FITC channel. For Cell cycle analysis, cells were incubated with 10 µg/mL BrdU for 1 hr, followed by surface staining, fixation, and permeabilization according to the manufacturer's (Phase-Flow Alexa Fluoro 647 BrdU Kit, Biolegend). Cells were then stained with antibodies against BrdU and 7AAD. Flow cytometry data were acquired on Novocyte (ACEA Biosciences) and were analyzed with FlowJo software (BD Biosciences).

Western blot analysis

For protein extraction, cells were harvested, lysed, and sonicated at 4 °C in a lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.5% SDS, 5 mM sodium pyrophosphate, protease, and phosphatase inhibitor tablet). Cell lysates were centrifuged at 13,000 × g for 15 min, and the supernatant was recovered. The protein concentrations were determined using the Pierce™ BCA Protein Assay kit (Thermo Fisher Scientific). The samples were boiled in NuPAGE® LDS Sample Buffer and Reducing solution (Thermo Fisher Scientific) for 5 min. The proteins were separated by NuPAGE 4-12% Protein Gels (Thermo Fisher Scientific), transferred to PVDF membranes by the iBlot Gel Transfer Device (Thermo Fisher Scientific), then incubated with primary antibodies (listed in supplemental Table 3), followed by incubating with the secondary antibodies conjugated with horseradish peroxidase. Immunoblots were developed on films using the enhanced chemiluminescence technique.

RNA extraction and RT-qPCR

RNeasy Mini Kit (Qiagen) was used for RNA isolation. Random hexamers and M-MLV Reverse Transcriptase (Invitrogen) was used for cDNA synthesis. BIO-RAD CFX96™ (or CFX384™) Real-Time PCR Detection System was used for SYBR green-based quantitative PCR. The relative gene expression was determined by the comparative CT method, also referred to as the 2^{-CT} method. The data were presented as the fold change in gene expression normalized to an internal reference gene (beta2-microglobulin) and relative to the control (the first sample in the group). Fold change = $2^{-C_T} = [(CT_{\text{gene of interest}} - CT_{\text{internal reference}}) \text{ sample A} - [(CT_{\text{gene of interest}} - CT_{\text{internal reference}}) \text{ sample B}]]$. Samples for each experimental condition were run in triplicated PCR reactions. Primers are listed in supplemental Table 4.

Radioactive tracer-based metabolic activity analysis.

The radioactive tracer-based metabolic assay was performed as described previously (75). Glycolysis was measured by the generation of $^3\text{H}_2\text{O}$ from [5- $^3\text{H}(\text{N})$] D-glucose, fatty acid oxidation was measured by the generation of $^3\text{H}_2\text{O}$ from [9,10- ^3H] palmitic acid, pentose phosphate pathway was measured by the generation of $^{14}\text{CO}_2$ from [1- ^{14}C] D-glucose, glutamine oxidation activity was measured by the generation of $^{14}\text{CO}_2$ from [U- ^{14}C]-glutamine. For catabolic activities generation of $^{14}\text{CO}_2$, five million T cells in 0.5 mL fresh media were dispensed into 7mL glass vials (TS-13028, Thermo) with a PCR tube containing 50 μL 0.2N NaOH glued on the sidewall. After adding 0.5 μCi radioactive tracer, the vials were capped using a screw cap with a rubber septum (TS-12713, Thermo) and incubated at 37 °C for 2 hrs. The assay was then stopped by injection of 100 μL 5N HCL into the vial. Vials were kept at room temperature overnight to trap the $^{14}\text{CO}_2$. The NaOH solution in the PCR tube was then transferred to scintillation vials containing 10mL scintillation solution for counting. A cell-free sample containing the same amount of tracer was included as a background control. For catabolic activities generating $^3\text{H}_2\text{O}$, 1 μCi radioactive tracer was added to the suspension of one million cells in 0.5mL fresh media in 48 wells, then incubated at 37 °C for 2 hrs. The assay was stopped by transferring samples to a 1.5 mL microcentrifuge tube containing 50 μL 5N HCL, which was placed in a 20 mL scintillation vial containing 0.5 mL water. Then the vial was capped and sealed. $^3\text{H}_2\text{O}$ was separated from other radio-labeled metabolites by evaporation diffusion overnight at room temperature. The 1.5 mL microcentrifuge tube was removed, and 10mL scintillation solution was added to the vial before counting. A cell-free sample containing 1 μCi radioactive tracer was included as a background control. To examine the incorporation of glutamine-derived carbon into the DNA/RNA, 0.5mM glutamine and 2 μCi [U- ^{14}C]-glutamine was added to 1.5×10^7 cells suspended with a glutamine-free medium and cultured for 6 hrs with IL2. RNA and DNA were isolated with Quick-DNA/RNA™ Miniprep Kit (Cat#: D7005). Radioactivity was measured by liquid scintillation counting and normalized to total DNA or RNA concentration.

Adoptive cell transfer and *in vivo* proliferation

For homeostatic proliferation in lymphopenic *Rag*^{-/-} mice, naïve CD4⁺ T cells isolated from donor mice were mixed with WT and KO cells at a 1:1 ratio and labeled with CFSE. Approximately 1×10^7 cells in 150 μL PBS were transferred via retro-orbital venous injection into 6–8-week-old gender-matched host mice. Mice were sacrificed after 5 days, and lymph nodes were extracted from host mice, then processed for surface staining and flow analysis.

For antigen-driven proliferation using OTII mice, naïve CD4⁺ T cells isolated from OTII/CD45.2 TCR transgenic donor mice were mixed with WT and KO cells at a 1:1 ratio and labeled with CFSE. Approximately 1×10^7 cells in 150 μL PBS were transferred via retro-orbital venous injection into 6–8-week-old gender-matched CD45.1 host mice. Host mice were immunized subcutaneously in the hock area (50 μL each site) in both legs with 1 mg/mL OVA³²³⁻³³⁹ peptide (InvivoGen) emulsified with CFA (InvivoGen). Mice were sacrificed after 7 days, and lymph organs were extracted from host mice then processed for surface staining, intracellular staining, and flow analysis.

Experimental Autoimmune Encephalomyelitis (EAE) Induction and Assessment

For induced EAE, mice were immunized subcutaneously with 100 μ g of myelin oligodendrocyte glycoprotein (MOG)₃₅₋₅₅ peptide emulsified in complete Freund adjuvant (CFA), which was made from IFA(Difco) plus mycobacterium tuberculosis (Difco). Mice were i.p. injected with 200 ng of pertussis toxin (List Biological) on the day of immunization and 2 days later. The mice were observed daily for clinical signs and scored as described previously (76).

Histopathology

Mice were euthanized and perfused with 25 mL PBS with 2mM EDTA by heart puncture to remove blood from internal organs. Cervical spinal cords were collected, fixed by 10% neutral buffered formalin solution, and decalcified. Tissues were then embedded in paraffin, sectioned, and stained with standard histological methods for Haematoxylin and Eosin (H&E) staining. Microscopy images were taken using Zeiss Axio Scope A1.

Metabolite quantification and stable isotope labeling

Gas Chromatography-Mass Spectrometry (GC-MS) Sample Preparation and Analysis—CD3⁺ T cells isolated from WT mice were activated for 36 hrs before being collected and re-seeded at the density of 2×10^6 cells /mL in conditional media (glucose and glutamine free RPMI-1640, 10%DFBS) containing 10 mM ¹³C₆-glucose + 4 mM glutamine or 4 mM ¹³C₅-glutamine + 10 mM glucose. After 0.5, 2, 6, 12 h, around ($\sim 1 \times 10^7$) were collected and washed with PBS 3 times before being snap-frozen (Fig. S1A-C). Naïve CD4⁺ T cells from WT and SDHB cKO were collected and snap-frozen (Fig. S12A).

GC-MS was performed as previously described(77), cell pellets were resuspended in 0.45 ml -20 °C methanol/ water (1:1 v/v) containing 20 μ M L-norvaline as internal standard. Further extraction was performed by adding 0.225 ml chloroform, vortexing, and centrifugation at 15,000 \times g for 5 min at 4 °C. The upper aqueous phase was evaporated under vacuum using a Speedvac centrifugal evaporator. Separate tubes containing varying amounts of standards were evaporated. Dried samples and standards were dissolved in 30 μ l 20 mg/ml isobutylhydroxylamine hydrochloride (TCI #I0387) in pyridine and incubated for 20 min at 80°C. An equal volume of N-tertbutyldimethylsilyl-N-methyltrifluoroacetamide (MTBSTFA) (Soltec Ventures) was added and incubated for 60 min at 80 °C. After derivatization, samples and standards were analyzed by GC-MS using an Rxi-5ms column (15 m x 0.25 i.d. x 0.25 μ m, Restek) installed in a Shimadzu QP-2010 Plus gas chromatograph-mass spectrometer (GC-MS). The GC-MS was programmed with an injection temperature of 250°C, 1.0 μ l injection volume, and a split ratio of 1/10. The GC oven temperature was initially 130°C for 4 min, rising to 250°C at 6°C/min, and to 280°C at 60°C/min with a final hold at this temperature for 2 min. GC flow rate, with helium as the carrier gas, was 50 cm/s. The GC-MS interface temperature was 300°C, and (electron impact) ion source temperature was 200°C, with 70 eV ionization voltage. Fractional labeling from ¹³C substrates and mass isotopomer distributions were calculated as described (77). Data from standards were used to construct standard curves in MetaQuant (78), from which metabolite amounts in samples were calculated. Metabolite amounts were

corrected for recovery of the internal standard and for ^{13}C labeling to yield total (labeled and unlabeled) quantities in nmol per sample and then adjusted per cell number.

Capillary electrophoresis–triple quadrupole/time-of-flight mass spectrometry (CE-QqQ/TOFMS) analysis— $\text{CD}3^+$ T cells (around $\sim 1 \times 10^7$ per sample) isolated from WT and *SDHB* cKO mice were activated for 30 hrs (Fig. 2G). T cells were collected by centrifugation ($300 \times g$ at 4°C for 5 min), washed twice with 5% mannitol solution (10 mL first and then 2 mL), then treated with 800 μL of methanol and vortexed for 30 sec to inactivate enzymes. The cell extract was treated with 550 μL of Milli-Q water containing internal standards (H3304-1002, Human Metabolome Technologies, inc., Tsuruoka, Japan) and vortexed for 30 sec. The extract was obtained and centrifuged at $2,300 \times g$ and 4°C for 5 min, and then 700 μL of the upper aqueous layer was centrifugally filtered through a Millipore 5-kDa cutoff filter at $9,100 \times g$ and 4°C for 180 min to remove proteins. For CE-MS analysis, the filtrate was centrifugally concentrated and resuspended in 50 μL of Milli-Q water. Cationic compounds were measured in the positive mode of CE-TOFMS, and anionic compounds were measured in the positive and negative modes of CE-MS/MS. Peaks detected by CE-TOFMS and CE-MS/MS were extracted using an automatic integration software (MasterHands, Keio University, Tsuruoka, Japan and MassHunter Quantitative Analysis B.04.00, Agilent Technologies, Santa Clara, CA, USA, respectively) to obtain peak information, including m/z , migration time (MT), and peak area. The peaks were annotated with putative metabolites from the HMT metabolite database based on their MTs in CE and m/z values determined by TOFMS. The tolerance range for the peak annotation was configured at ± 0.5 min for MT and ± 10 ppm for m/z . In addition, concentrations of metabolites were calculated by normalizing the peak area of each metabolite with respect to the area of the internal standard and by using standard curves, which were obtained by three-point calibrations.

Metabolite extraction and analysis by ion chromatography-ultra high resolution-Fourier transform mass spectrometry (IC-UHR-FTMS)— $\text{CD}3^+$ T Cells (Fig. 2E and S8B) were cultured in conditional media (glutamine-free RPMI-1640, 10%DFBS) containing 2 mM $^{13}\text{C}_5$ -Glutamine for 30 h. $\sim 1 \times 10^7$ cells for each sample were collected and washed 3 times with cold PBS before being snap-frozen. Naïve $\text{CD}4^+$ T cells were polarized under $\text{T}_{\text{H}0}$, $\text{T}_{\text{H}1}$, $\text{T}_{\text{H}17}$, and iT_{reg} culture for 72 h (Fig. S8E). Cells were collected and washed with cold PBS 3 times before snap freezing. The frozen cell pellets were homogenized in 60% cold CH_3CN in a ball mill (Precellys- 24, Bertin Technologies) for denaturing proteins and optimizing extraction. Polar metabolites were extracted by the solvent partitioning method with a final $\text{CH}_3\text{CN}:\text{H}_2\text{O}:\text{CHCl}_3$ (2:1.5:1, v/v) ratio, as described previously(79). The polar extracts were reconstituted in nanopure water before analysis on a Dionex ICS-5000+ ion chromatography system interfaced with a Thermo Fusion Orbitrap Tribrid mass spectrometer (Thermo Fisher Scientific) as previously described(80) using a m/z scan range of 80-700. Peak areas were integrated and exported to Excel via the Thermo TraceFinder (version 3.3) software package before natural abundance correction (81). The isotopologue distributions of metabolites were calculated as the mole fractions as previously described (82). The number of moles of each metabolite was determined by calibrating the natural abundance-corrected signal against authentic external

standards. The amount was normalized to the amount of extracted protein and is reported in nmol/mg protein.

Succinate and α -KG quantification—CD4⁺ T cells were treated with 100 μ M NV118 or 10mM α -KG in a naive condition for 24 h (Fig.S8C). Cells were collected for quantifying succinate and α -KG using the succinate colorimetric assay kit (Abcam, ab204718) or α -KG assay kit (Abcam, ab83431). The optical density (OD) values were measured at 450 nm and 570 nm with a Synergy 2 microplate reader (BioTek).

LEGENDplex™ Bead-Based Immunoassay—The supernatants from 36 hrs activated CD4⁺ T cells were collected for quantifying cytokines using LEGENDplex™ Mouse Th Cytokine Panel (13-plex) V02 kit (Cat. No 740741-V-bottom, Bio Legend, San Diego, USA). The data were collected by Novocyte (ACEA Biosciences) and analyzed using LEGENDplex™ Data Analysis Software V8.0 (BioLegend).

RNA-seq analysis—For RNA sequencing analysis, total RNA was extracted using RNeasy Mini Kit (Qiagen) and treated with DNase I according to the manufacturer's instructions. After assessing the quality of total RNA using an Agilent 2100 Bioanalyzer and RNA Nanochip (Agilent Technologies), 150 ng total RNA was treated to deplete the levels of ribosomal RNA (rRNA) using target-specific oligos combined with rRNA removal beads. Following rRNA removal, mRNA was fragmented and converted into double-stranded cDNA. Adaptor-ligated cDNA was amplified by limit cycle PCR. After library quality was determined via Agilent 4200 TapeStation and quantified by KAPA qPCR, approximately 60 million paired-end 150 bp sequence reads were generated on the Illumina HiSeq 4000 platform. Quality control and adapter trimming were accomplished using the FastQC (version 0.11.3) and Trim Galore (version 0.4.0) software packages. Trimmed reads were mapped to the Genome Reference Consortium GRCm38 (mm10) murine genome assembly using TopHat2 (version 2.1.0), and feature counts were generated using HTSeq (version 0.6.1). Statistical analysis for differential expression was performed using the DESeq2 package (version 1.16.1) in R, with the default Benjamini-Hochberg *p-value* adjustment method. The Ingenuity Pathway Analysis (IPA) software (QIAGEN), the Gene Set Enrichment Analysis (GSEA) software (UC San Diego, BROAD Ins.), and the R Programming Language software were used to analyze gene signature and pathway enrichment.

ATAC-seq analysis—ATAC-seq was performed as previously described (83) with only minor modifications. 5×10^4 cells per experiment were first washed with RSB buffer (10 mM Tris-HCl pH 8, 10 mM NaCl, 3 mM MgCl₂) and gently permeabilized with RSB lysis buffer (10 mM Tris-HCl pH 8, 10 mM NaCl, 3 mM MgCl₂, 0.1% NP-40) on ice. Cells were suspended in 50 μ L of tagmentation master mix prepared from Illumina Tagment DNA TDE1 Enzyme and Buffer Kit components (#20034197), and transposition was performed for 30 minutes at 37°C. Tagmented DNA fragments were isolated using Qiagen MinElute PCR Purification columns prior to library amplification. ATAC-seq libraries were amplified with barcoded Nextera primers for 14 cycles, and excess primers were removed by size selection with AMPure XP beads. Libraries were sequenced on the HiSeq4000

platform running in PEx150bp mode. The ENCODE ATAC-seq pipeline (<https://github.com/ENCODE-DCC/atac-seq-pipeline>) with default parameters was used to process ATAC-seq data. First, reads are scanned for adaptor sequences and trimmed with cutadapt (version 2.3). Reads are then mapped to mm10 with bowtie2 (version 2.3.4.3). Properly aligned, non-mitochondrial read pairs were retained for peak calling with MACS2 (version 2.2.4). Differential ATAC peak analysis was completed using DiffBind (Bioconductor) and DESeq2 with an FDR < 0.05. Once differential peaks were called, heatmaps were generated with deeptools (version 3.3.1)(84), motif analysis was performed using HOMER (version 4.11.1) (85), and nearby genes were identified using GREAT (86).

CHIP-qPCR—ChIP was performed as described previously(87). Briefly, $\sim 10^7$ cells were cross-linked with 1% methanol-free formaldehyde for 10 min at room temperature. The fixation was quenched by adding glycine to a final concentration of 125 mM and placed on ice for 5 minutes. Fixed cells were pelleted at $1,200 \times g$ for 5 minutes at 4°C and resuspended in ice-cold PBS containing a protease inhibitor cocktail. Samples were sonicated with an Active Motif EpiShear probe sonicator. After sonication, a 5 μ L volume was aliquoted from each sample (input) and combined with 20 μ L TE, 1 μ L 10% SDS, and 1 μ L 20 mg/mL Proteinase K for overnight decrosslinking at 65°C. Input samples were purified using Qiagen MinElute PCR Purification columns, and chromatin fragmentation was assessed by gel electrophoresis on an E-Gel 2% EX agarose gel. The cleared chromatin solutions were immunoprecipitated with antibodies against H3K4me3 (ab8580; Abcam). The normal rabbit IgG (ab171870; Abcam) was used as a background control. Immunoprecipitated complexes were isolated with protein A Dynabeads. ChIP DNA was purified with Qiagen MinElute PCR Purification columns. The DNA was used for ChIP-qPCR with specific *Prdm1* PCR primers (supplemental Table 5). BIO-RAD CFX96™ Real-Time PCR Detection System was used for SYBR green-based quantitative PCR. The data are presented as fold enrichment over the input control.

CRISPR-Cas 9—All guide RNAs, Alt-R S.p. HIFI Cas9 Nuclease V3, and Alt-R S.p. HIFI electroporation enhancer were purchased from IDT. Mixed 60 pmol of Cas9 protein with 150 pmol of sgRNA and incubated for 20 minutes at room temperature for Cas9/RNP complex formation. Then, activated CD4⁺ T cells were resuspended in P4 Primary Cell buffer (Lonza) and mixed with the RNP complexes and 4 μ M Electroporation Enhancer in P4 Primary Cell buffer (Lonza), transferred the cell/CRISPR mixture to the bottom hole of the wells of the Lonza nucleofector strip for electroporation by using Lonza nucleofector (Program CM137), electroporated cells were recovered in T cell culture medium for 2 h prior to activation with anti-CD3/CD28 antibodies, or under T_H1 or T_H17 polarization. Duplexes of two separate guides per target gene were used: Mm.Cas9.*Prdm1.1AA* (ACACGCTTTGGACCCCTCAT), Mm.Cas9.*Prdm1.1AB* (CATAGTGAACGACCACCCT).

Statistical analysis

Statistical analysis was conducted using the GraphPad Prism software (GraphPad Software, Inc.). Unpaired two-tail Student's t-test, multiple comparisons of one/ two-way ANOVA were used to assess differences in other experiments. *P* values smaller than 0.05 were

considered significant, with $p < 0.05$, $p < 0.01$, $p < 0.001$, and $p < 0.0001$ indicated as *, **, ***, and ****, respectively.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Funding: This work was supported by 1U01CA232488-01 from the National Institute of Health (Cancer Moonshot program), 2R01AI114581-06, and R01CA247941 from the National Institute of Health, V2014-001 from the V-Foundation, and 128436-RSG-15-180-01-LIB from the American Cancer Society (to RW). The Sanford Burnham Prebys Cancer Metabolism Core was supported by the SBP NCI Cancer Center Support Grant P30 CA030199. The Center for Environmental and Systems Biochemistry Core was supported by the Markey Cancer Center support grant P30CA177558.

Data availability statement:

The CD3⁺ T cells RNA-seq datasets generated for this study can be found in the GEO accession GSE184010. The CD4⁺ T cells RNA-seq datasets generated for this study can be found in the GEO accession GSE184743. The CD4⁺ T cells ATAC-seq datasets generated for this study can be found in the GEO accession GSE184742. SDHB-flox mouse strain is available from Dr. Ruoning Wang's laboratory under a material transfer agreement with the Nationwide Children's Hospital. All data needed to evaluate the conclusions in the paper are present in the paper or the Supplementary Materials.

Reference and notes

1. Sena LA, Li S, Jairaman A, Prakriya M, Ezponda T, Hildeman DA, Wang CR, Schumacker PT, Licht JD, Perlman H, Bryce PJ, Chandel NS, Mitochondria are required for antigen-specific T cell activation through reactive oxygen species signaling. *Immunity* 38, 225–236 (2013). [PubMed: 23415911]
2. Gerriets VA, Rathmell JC, Metabolic pathways in T cell fate and function. *Trends Immunol* 33, 168–173 (2012). [PubMed: 22342741]
3. Pearce EL, Pearce EJ, Metabolic pathways in immune cell activation and quiescence. *Immunity* 38, 633–643 (2013). [PubMed: 23601682]
4. Dang CV, MYC, metabolism, cell growth, and tumorigenesis. *Cold Spring Harbor perspectives in medicine* 3, (2013).
5. Pavlova NN, Thompson CB, The Emerging Hallmarks of Cancer Metabolism. *Cell Metab* 23, 27–47 (2016). [PubMed: 26771115]
6. Gate RE, Cheng CS, Aiden AP, Siba A, Tabaka M, Lituiev D, Machol I, Gordon MG, Subramaniam M, Shamim M, Hougén KL, Wortman I, Huang SC, Durand NC, Feng T, De Jager PL, Chang HY, Aiden EL, Benoist C, Beer MA, Ye CJ, Regev A, Genetic determinants of co-accessible chromatin regions in activated T cells across humans. *Nat Genet* 50, 1140–1150 (2018). [PubMed: 29988122]
7. Calderon D, Nguyen MLT, Mezger A, Kathiria A, Muller F, Nguyen V, Lescano N, Wu B, Trombetta J, Ribado JV, Knowles DA, Gao Z, Blaesche F, Parent AV, Burt TD, Anderson MS, Criswell LA, Greenleaf WJ, Marson A, Pritchard JK, Landscape of stimulation-responsive chromatin across diverse human immune cells. *Nat Genet* 51, 1494–1505 (2019). [PubMed: 31570894]
8. Ivanov II, Atarashi K, Manel N, Brodie EL, Shima T, Karaoz U, Wei D, Goldfarb KC, Santee CA, Lynch SV, Tanoue T, Imaoka A, Itoh K, Takeda K, Umesaki Y, Honda K, Littman DR, Induction of intestinal Th17 cells by segmented filamentous bacteria. *Cell* 139, 485–498 (2009). [PubMed: 19836068]

9. Wilson CB, Rowell E, Sekimata M, Epigenetic control of T-helper-cell differentiation. *Nat Rev Immunol* 9, 91–105 (2009). [PubMed: 19151746]
10. Oestreich KJ, Weinmann AS, Encoding stability versus flexibility: lessons learned from examining epigenetics in T helper cell differentiation. *Curr Top Microbiol Immunol* 356, 145–164 (2012). [PubMed: 21748629]
11. Owen OE, Kalhan SC, Hanson RW, The key role of anaplerosis and cataplerosis for citric acid cycle function. *J Biol Chem* 277, 30409–30412 (2002). [PubMed: 12087111]
12. Martinez-Reyes I, Chandel NS, Mitochondrial TCA cycle metabolites control physiology and disease. *Nat Commun* 11, 102 (2020). [PubMed: 31900386]
13. Murphy MP, O'Neill LAJ, Krebs Cycle Reimagined: The Emerging Roles of Succinate and Itaconate as Signal Transducers. *Cell* 174, 780–784 (2018). [PubMed: 30096309]
14. Xiao M, Yang H, Xu W, Ma S, Lin H, Zhu H, Liu L, Liu Y, Yang C, Xu Y, Zhao S, Ye D, Xiong Y, Guan KL, Inhibition of alpha-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. *Genes Dev* 26, 1326–1338 (2012). [PubMed: 22677546]
15. Walport LJ, Hopkinson RJ, Schofield CJ, Mechanisms of human histone and nucleic acid demethylases. *Curr Opin Chem Biol* 16, 525–534 (2012). [PubMed: 23063108]
16. van der Knaap JA, Verrijzer CP, Undercover: gene control by metabolites and metabolic enzymes. *Genes Dev* 30, 2345–2369 (2016). [PubMed: 27881599]
17. Tsukada Y, Fang J, Erdjument-Bromage H, Warren ME, Borchers CH, Tempst P, Zhang Y, Histone demethylation by a family of JmjC domain-containing proteins. *Nature* 439, 811–816 (2006). [PubMed: 16362057]
18. Gottlieb E, Tomlinson IP, Mitochondrial tumour suppressors: a genetic and biochemical update. *Nat Rev Cancer* 5, 857–866 (2005). [PubMed: 16327764]
19. King A, Selak MA, Gottlieb E, Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer. *Oncogene* 25, 4675–4682 (2006). [PubMed: 16892081]
20. Andrejeva G, Rathmell JC, Similarities and Distinctions of Cancer and Immune Metabolism in Inflammation and Tumors. *Cell Metab* 26, 49–70 (2017). [PubMed: 28683294]
21. Bailis W, Shyer JA, Zhao J, Canaveras JCG, Al Khazal FJ, Qu R, Steach HR, Bielecki P, Khan O, Jackson R, Kluger Y, Maher LJ 3rd, Rabinowitz J, Craft J, Flavell RA, Distinct modes of mitochondrial metabolism uncouple T cell differentiation and function. *Nature* 571, 403–407 (2019). [PubMed: 31217581]
22. Ehinger JK, Piel S, Ford R, Karlsson M, Sjoval F, Frostner EA, Morota S, Taylor RW, Turnbull DM, Cornell C, Moss SJ, Metzsch C, Hansson MJ, Fliri H, Elmer E, Cell-permeable succinate prodrugs bypass mitochondrial complex I deficiency. *Nat Commun* 7, 12317 (2016). [PubMed: 27502960]
23. Miyadera H, Shiomi K, Ui H, Yamaguchi Y, Masuma R, Tomoda H, Miyoshi H, Osanai A, Kita K, Omura S, Atpenins, potent and specific inhibitors of mitochondrial complex II (succinate-ubiquinone oxidoreductase). *Proceedings of the National Academy of Sciences of the United States of America* 100, 473–477 (2003). [PubMed: 12515859]
24. Wang R, Dillon CP, Shi LZ, Milasta S, Carter R, Finkelstein D, McCormick LL, Fitzgerald P, Chi H, Munger J, Green DR, The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. *Immunity* 35, 871–882 (2011). [PubMed: 22195744]
25. Mathews CK, Deoxyribonucleotide metabolism, mutagenesis and cancer. *Nat Rev Cancer* 15, 528–539 (2015). [PubMed: 26299592]
26. Quinlan CL, Orr AL, Perevoshchikova IV, Treberg JR, Ackrell BA, Brand MD, Mitochondrial complex II can generate reactive oxygen species at high rates in both the forward and reverse reactions. *J Biol Chem* 287, 27255–27264 (2012). [PubMed: 22689576]
27. Diaz-Castro B, Pintado CO, Garcia-Flores P, Lopez-Barneo J, Piruat JJ, Differential impairment of catecholaminergic cell maturation and survival by genetic mitochondrial complex II dysfunction. *Mol Cell Biol* 32, 3347–3357 (2012). [PubMed: 22711987]
28. Eltzschig HK, Carmeliet P, Hypoxia and inflammation. *N Engl J Med* 364, 656–665 (2011). [PubMed: 21323543]

29. Palazon A, Goldrath AW, Nizet V, Johnson RS, HIF transcription factors, inflammation, and immunity. *Immunity* 41, 518–528 (2014). [PubMed: 25367569]
30. Raghuraman S, Donkin I, Versteyhe S, Barres R, Simar D, The Emerging Role of Epigenetics in Inflammation and Immunometabolism. *Trends Endocrinol Metab* 27, 782–795 (2016). [PubMed: 27444065]
31. Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, Ito S, Yang C, Wang P, Xiao MT, Liu LX, Jiang WQ, Liu J, Zhang JY, Wang B, Frye S, Zhang Y, Xu YH, Lei QY, Guan KL, Zhao SM, Xiong Y, Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. *Cancer Cell* 19, 17–30 (2011). [PubMed: 21251613]
32. Bird JJ, Brown DR, Mullen AC, Moskowitz NH, Mahowald MA, Sider JR, Gajewski TF, Wang CR, Reiner SL, Helper T cell differentiation is controlled by the cell cycle. *Immunity* 9, 229–237 (1998). [PubMed: 9729043]
33. Yang C, Matro JC, Huntoon KM, Ye DY, Huynh TT, Flidner SM, Breza J, Zhuang Z, Pacak K, Missense mutations in the human SDHB gene increase protein degradation without altering intrinsic enzymatic function. *FASEB J* 26, 4506–4516 (2012). [PubMed: 22835832]
34. Lee P, Chandel NS, Simon MC, Cellular adaptation to hypoxia through hypoxia inducible factors and beyond. *Nat Rev Mol Cell Biol* 21, 268–283 (2020). [PubMed: 32144406]
35. Semenza GL, Hypoxia-inducible factors in physiology and medicine. *Cell* 148, 399–408 (2012). [PubMed: 22304911]
36. Tannahill GM, Curtis AM, Adamik J, Palsson-McDermott EM, McGettrick AF, Goel G, Frezza C, Bernard NJ, Kelly B, Foley NH, Zheng L, Gardet A, Tong Z, Jany SS, Corr SC, Haneklaus M, Caffrey BE, Pierce K, Walmsley S, Beasley FC, Cummins E, Nizet V, Whyte M, Taylor CT, Lin H, Masters SL, Gottlieb E, Kelly VP, Clish C, Auron PE, Xavier RJ, O'Neill LA, Succinate is an inflammatory signal that induces IL-1beta through HIF-1alpha. *Nature* 496, 238–242 (2013). [PubMed: 23535595]
37. Dang EV, Barbi J, Yang HY, Jinasena D, Yu H, Zheng Y, Bordman Z, Fu J, Kim Y, Yen HR, Luo W, Zeller K, Shimoda L, Topalian SL, Semenza GL, Dang CV, Pardoll DM, Pan F, Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1. *Cell* 146, 772–784 (2011). [PubMed: 21871655]
38. Liu L, Lu Y, Martinez J, Bi Y, Lian G, Wang T, Milasta S, Wang J, Yang M, Liu G, Green DR, Wang R, Proinflammatory signal suppresses proliferation and shifts macrophage metabolism from Myc-dependent to HIF1alpha-dependent. *Proceedings of the National Academy of Sciences of the United States of America* 113, 1564–1569 (2016). [PubMed: 26811453]
39. Kouzarides T, Chromatin modifications and their function. *Cell* 128, 693–705 (2007). [PubMed: 17320507]
40. Wu X, Zhang Y, TET-mediated active DNA demethylation: mechanism, function and beyond. *Nat Rev Genet* 18, 517–534 (2017). [PubMed: 28555658]
41. Gaffen SL, Jain R, Garg AV, Cua DJ, The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. *Nat Rev Immunol* 14, 585–600 (2014). [PubMed: 25145755]
42. Jain R, Chen Y, Kanno Y, Joyce-Shaikh B, Vahedi G, Hirahara K, Blumenschein WM, Sukumar S, Haines CJ, Sadekova S, McClanahan TK, McGeachy MJ, O'Shea JJ, Cua DJ, Interleukin-23-Induced Transcription Factor Blimp-1 Promotes Pathogenicity of T Helper 17 Cells. *Immunity* 44, 131–142 (2016). [PubMed: 26750311]
43. Beach TE, Prag HA, Pala L, Logan A, Huang MM, Gruszczuk AV, Martin JL, Mahbubani K, Hamed MO, Hosgood SA, Nicholson ML, James AM, Hartley RC, Murphy MP, Saeb-Parsy K, Targeting succinate dehydrogenase with malonate ester prodrugs decreases renal ischemia reperfusion injury. *Redox Biol* 36, 101640 (2020). [PubMed: 32863205]
44. Johansson C, Tumber A, Che K, Cain P, Nowak R, Gileadi C, Oppermann U, The roles of Jumonji-type oxygenases in human disease. *Epigenomics* 6, 89–120 (2014). [PubMed: 24579949]
45. Dou Y, Milne TA, Tackett AJ, Smith ER, Fukuda A, Wysocka J, Allis CD, Chait BT, Hess JL, Roeder RG, Physical association and coordinate function of the H3 K4 methyltransferase MLL1 and the H4 K16 acetyltransferase MOF. *Cell* 121, 873–885 (2005). [PubMed: 15960975]
46. Johansson C, Velupillai S, Tumber A, Szykowska A, Hookway ES, Nowak RP, Strain-Damerell C, Gileadi C, Philpott M, Burgess-Brown N, Wu N, Kopec J, Nuzzi A, Steuber H, Egner U,

- Badock V, Munro S, LaThangue NB, Westaway S, Brown J, Athanasou N, Prinjha R, Brennan PE, Oppermann U, Structural analysis of human KDM5B guides histone demethylase inhibitor development. *Nature chemical biology* 12, 539–545 (2016). [PubMed: 27214403]
47. Karatas H, Townsend EC, Cao F, Chen Y, Bernard D, Liu L, Lei M, Dou Y, Wang S, High-affinity, small-molecule peptidomimetic inhibitors of MLL1/WDR5 protein-protein interaction. *J Am Chem Soc* 135, 669–682 (2013). [PubMed: 23210835]
48. Weis S, Carlos AR, Moita MR, Singh S, Blankenhaus B, Cardoso S, Larsen R, Rebelo S, Schauble S, Del Barrio L, Mithieux G, Rajas F, Lindig S, Bauer M, Soares MP, Metabolic Adaptation Establishes Disease Tolerance to Sepsis. *Cell* 169, 1263–1275 e1214 (2017). [PubMed: 28622511]
49. Weinberg ED, Nutritional immunity. Host's attempt to withhold iron from microbial invaders. *JAMA* 231, 39–41 (1975). [PubMed: 1243565]
50. Slack M, Wang T, Wang R, T cell metabolic reprogramming and plasticity. *Molecular immunology* 68, 507–512 (2015). [PubMed: 26277274]
51. Troha K, Ayres JS, Metabolic Adaptations to Infections at the Organismal Level. *Trends Immunol* 41, 113–125 (2020). [PubMed: 31959515]
52. Chi H, Regulation and function of mTOR signalling in T cell fate decisions. *Nature Reviews Immunology* 12, 325–338 (2012).
53. Powell JD, Delgoffe GM, The mammalian target of rapamycin: linking T cell differentiation, function, and metabolism. *Immunity* 33, 301–311 (2010). [PubMed: 20870173]
54. Michalek RD, Rathmell JC, The metabolic life and times of a T-cell. *Immunol Rev* 236, 190–202 (2010). [PubMed: 20636818]
55. Birsoy K, Wang T, Chen WW, Freinkman E, Abu-Remaileh M, Sabatini DM, An Essential Role of the Mitochondrial Electron Transport Chain in Cell Proliferation Is to Enable Aspartate Synthesis. *Cell* 162, 540–551 (2015). [PubMed: 26232224]
56. Phan AT, Goldrath AW, Glass CK, Metabolic and Epigenetic Coordination of T Cell and Macrophage Immunity. *Immunity* 46, 714–729 (2017). [PubMed: 28514673]
57. Russ BE, Prier JE, Rao S, Turner SJ, T cell immunity as a tool for studying epigenetic regulation of cellular differentiation. *Front Genet* 4, 218 (2013). [PubMed: 24273551]
58. Sullivan LB, Gui DY, Hosios AM, Bush LN, Freinkman E, Vander Heiden MG, Supporting Aspartate Biosynthesis Is an Essential Function of Respiration in Proliferating Cells. *Cell* 162, 552–563 (2015). [PubMed: 26232225]
59. Gui DY, Sullivan LB, Luengo A, Hosios AM, Bush LN, Gitego N, Davidson SM, Freinkman E, Thomas CJ, Vander Heiden MG, Environment Dictates Dependence on Mitochondrial Complex I for NAD⁺ and Aspartate Production and Determines Cancer Cell Sensitivity to Metformin. *Cell Metab* 24, 716–727 (2016). [PubMed: 27746050]
60. Gaude E, Schmidt C, Gammage PA, Dugourd A, Blacker T, Chew SP, Saez-Rodriguez J, O'Neill JS, Szabadkai G, Minczuk M, Frezza C, NADH Shuttling Couples Cytosolic Reductive Carboxylation of Glutamine with Glycolysis in Cells with Mitochondrial Dysfunction. *Mol Cell* 69, 581–593 e587 (2018). [PubMed: 29452638]
61. Cardaci S, Zheng L, MacKay G, van den Broek NJ, MacKenzie ED, Nixon C, Stevenson D, Tumanov S, Bulusu V, Kamphorst JJ, Vazquez A, Fleming S, Schiavi F, Kalna G, Blyth K, Strathdee D, Gottlieb E, Pyruvate carboxylation enables growth of SDH-deficient cells by supporting aspartate biosynthesis. *Nat Cell Biol* 17, 1317–1326 (2015). [PubMed: 26302408]
62. Lussey-Lepoutre C, Hollinshead KE, Ludwig C, Menara M, Morin A, Castro-Vega LJ, Parker SJ, Janin M, Martinelli C, Ottolenghi C, Metallo C, Gimenez-Roqueplo AP, Favier J, Tennant DA, Loss of succinate dehydrogenase activity results in dependency on pyruvate carboxylation for cellular anabolism. *Nat Commun* 6, 8784 (2015). [PubMed: 26522426]
63. Mills EL, Kelly B, Logan A, Costa ASH, Varma M, Bryant CE, Tourlomousis P, Dabritz JHM, Gottlieb E, Latorre I, Corr SC, McManus G, Ryan D, Jacobs HT, Szibor M, Xavier RJ, Braun T, Frezza C, Murphy MP, O'Neill LA, Succinate Dehydrogenase Supports Metabolic Repurposing of Mitochondria to Drive Inflammatory Macrophages. *Cell* 167, 457–470 e413 (2016). [PubMed: 27667687]
64. Nastasi C, Willerlev-Olsen A, Dalhoff K, Ford SL, Gadsboll AO, Buus TB, Gluud M, Danielsen M, Litman T, Bonefeld CM, Geisler C, Odum N, Woetmann A, Inhibition of succinate

- dehydrogenase activity impairs human T cell activation and function. *Sci Rep* 11, 1458 (2021). [PubMed: 33446766]
65. Mills E, O'Neill LA, Succinate: a metabolic signal in inflammation. *Trends Cell Biol* 24, 313–320 (2014). [PubMed: 24361092]
 66. Artyomov MN, Sergushichev A, Schilling JD, Integrating immunometabolism and macrophage diversity. *Semin Immunol* 28, 417–424 (2016). [PubMed: 27771140]
 67. Lampropoulou V, Sergushichev A, Bambouskova M, Nair S, Vincent EE, Loginicheva E, Cervantes-Barragan L, Ma X, Huang SC, Griss T, Weinheimer CJ, Khader S, Randolph GJ, Pearce EJ, Jones RG, Diwan A, Diamond MS, Artyomov MN, Itaconate Links Inhibition of Succinate Dehydrogenase with Macrophage Metabolic Remodeling and Regulation of Inflammation. *Cell Metab* 24, 158–166 (2016). [PubMed: 27374498]
 68. Swain A, Bambouskova M, Kim H, Andhey PS, Duncan D, Auclair K, Chubukov V, Simons DM, Roddy TP, Stewart KM, Artyomov MN, Comparative evaluation of itaconate and its derivatives reveals divergent inflammasome and type I interferon regulation in macrophages. *Nat Metab* 2, 594–602 (2020). [PubMed: 32694786]
 69. He W, Miao FJ, Lin DC, Schwandner RT, Wang Z, Gao J, Chen JL, Tian H, Ling L, Citric acid cycle intermediates as ligands for orphan G-protein-coupled receptors. *Nature* 429, 188–193 (2004). [PubMed: 15141213]
 70. Ryan DG, Murphy MP, Frezza C, Prag HA, Chouchani ET, O'Neill LA, Mills EL, Coupling Krebs cycle metabolites to signalling in immunity and cancer. *Nat Metab* 1, 16–33 (2019). [PubMed: 31032474]
 71. Weinberg SE, Singer BD, Steinert EM, Martinez CA, Mehta MM, Martinez-Reyes I, Gao P, Helmin KA, Abdala-Valencia H, Sena LA, Schumacker PT, Turka LA, Chandel NS, Mitochondrial complex III is essential for suppressive function of regulatory T cells. *Nature* 565, 495–499 (2019). [PubMed: 30626970]
 72. Skarnes WC, Rosen B, West AP, Koutsourakis M, Bushell W, Iyer V, Mujica AO, Thomas M, Harrow J, Cox T, Jackson D, Severin J, Biggs P, Fu J, Nefedov M, de Jong PJ, Stewart AF, Bradley A, A conditional knockout resource for the genome-wide study of mouse gene function. *Nature* 474, 337–342 (2011). [PubMed: 21677750]
 73. Ryan HE, Poloni M, McNulty W, Elson D, Gassmann M, Arbeit JM, Johnson RS, Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth. *Cancer Res* 60, 4010–4015 (2000). [PubMed: 10945599]
 74. Habib M, Fares F, Bourgeois CA, Bella C, Bernardino J, Hernandez-Blazquez F, de Capoa A, Niveleau A, DNA global hypomethylation in EBV-transformed interphase nuclei. *Exp Cell Res* 249, 46–53 (1999). [PubMed: 10328952]
 75. Chen X, Sherman JW, Wang R, Radioisotope-Based Protocol for Determination of Central Carbon Metabolism in T Cells. *Methods Mol Biol* 2111, 257–265 (2020). [PubMed: 31933213]
 76. Shi LZ, Wang R, Huang G, Vogel P, Neale G, Green DR, Chi H, HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells. *J Exp Med* 208, 1367–1376 (2011). [PubMed: 21708926]
 77. Ratnikov B, Aza-Blanc P, Ronai ZA, Smith JW, Osterman AL, Scott DA, Glutamate and asparagine cataplerosis underlie glutamine addiction in melanoma. *Oncotarget* 6, 7379–7389 (2015). [PubMed: 25749035]
 78. Bunk B, Kucklick M, Jonas R, Munch R, Schobert M, Jahn D, Hiller K, MetaQuant: a tool for the automatic quantification of GC/MS-based metabolome data. *Bioinformatics* 22, 2962–2965 (2006). [PubMed: 17046977]
 79. T.W.M F, Considerations of Sample Preparation for Metabolomics Investigation. In: Fan TM, Lane A, Higashi R (eds) *The Handbook of Metabolomics. Methods in Pharmacology and Toxicology*, (2012).
 80. Fan TW, Warmoes MO, Sun Q, Song H, Turchan-Cholewo J, Martin JT, Mahan A, Higashi RM, Lane AN, Distinctly perturbed metabolic networks underlie differential tumor tissue damages induced by immune modulator beta-glucan in a two-case ex vivo non-small-cell lung cancer study. *Cold Spring Harb Mol Case Stud* 2, a000893 (2016). [PubMed: 27551682]

81. Moseley HN, Correcting for the effects of natural abundance in stable isotope resolved metabolomics experiments involving ultra-high resolution mass spectrometry. *BMC Bioinformatics* 11, 139 (2010). [PubMed: 20236542]
82. Lane AN, Fan TW, Higashi RM, Isotopomer-based metabolomic analysis by NMR and mass spectrometry. *Methods Cell Biol* 84, 541–588 (2008). [PubMed: 17964943]
83. Buenrostro JD, Giresi PG, Zaba LC, Chang HY, Greenleaf WJ, Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position. *Nat Methods* 10, 1213–1218 (2013). [PubMed: 24097267]
84. Ramirez F, Ryan DP, Gruning B, Bhardwaj V, Kilpert F, Richter AS, Heyne S, Dundar F, Manke T, deepTools2: a next generation web server for deep-sequencing data analysis. *Nucleic Acids Res* 44, W160–165 (2016). [PubMed: 27079975]
85. Heinz S, Benner C, Spann N, Bertolino E, Lin YC, Laslo P, Cheng JX, Murre C, Singh H, Glass CK, Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. *Mol Cell* 38, 576–589 (2010). [PubMed: 20513432]
86. McLean CY, Bristor D, Hiller M, Clarke SL, Schaar BT, Lowe CB, Wenger AM, Bejerano G, GREAT improves functional interpretation of cis-regulatory regions. *Nat Biotechnol* 28, 495–501 (2010). [PubMed: 20436461]
87. Sunkel BD, Wang M, LaHaye S, Kelly BJ, Fitch JR, Barr FG, White P, Stanton BZ, Evidence of pioneer factor activity of an oncogenic fusion transcription factor. *iScience* 24, 102867 (2021). [PubMed: 34386729]




Figure 1. SDHB is required for the T cell proliferation and survival.

(A) SDHB mRNA and protein levels of the indicated T cells were determined by qPCR and Immunoblot (n=3), *** $p < 0.001$, Student's t test. (B) Metabolites of the indicated T cells were determined by CE-QqQ/TOFMS (n=3), ** $p < 0.01$, *** $p < 0.001$, Student's t test. (C) The cell cycle profile of the indicated CD4⁺ T cells was analyzed by BrdU and 7AAD staining. The numbers indicate the percentage of cells in the cell cycle stage. (D) Cell proliferation of the indicated CD4⁺ T cells was determined by CFSE dilution. (E-F) Cell viability of the indicated CD4⁺ T cells was assessed by 7AAD uptake, n=3, data are representative of 3 independent experiments, n.s., not significant, *** $p < 0.001$, one-way ANOVA. T cells (B-F) were activated by the plate-bound anti-CD3/CD28 antibodies. (G)

Diagram of *in vivo* competitive proliferation experimental procedure (top panel). The donor CD4⁺ T cell ratios before and after adoptive transfer were evaluated by surface staining of isogenic markers, and cell proliferation was evaluated by CFSE dilution (bottle panel). Representative flow plots of the donor T cells were gated from TCRβ⁺CD4⁺ cells and parsed by Thy1.1(WT) and Thy1.2(*SDHB* cKO). Data represent 3 independent experiments. **(H)** Diagram of *in vivo* antigen-specific competitive proliferation experimental procedure (top panel), the donor CD4⁺ T cell ratios before and after adoptive transfer were evaluated by surface staining of isogenic markers, and cell proliferation was evaluated by CFSE dilution (bottle panel). Representative flow plots of the donor T cells were gated from CD45.2⁺CD4⁺ cells and parsed by Thy1.1(WT) and Thy1.2(*SDHB* cKO). Data represent of 3 independent experiments. **(I)** Diagram of EAE experimental procedure (left panel), clinical scores were evaluated daily (right panel), n=5 mice for each group, experiments were repeated 3 times. **(J)** H&E staining of spinal cord sections from WT and *SDHB* cKO mice after EAE induction, leukocyte infiltration are marked by arrowheads. Scale bar, 200μm. Bar graphs, mean ± SEM.




Figure 2. SDHB deficiency decouples the TCA cycle from nucleoside biosynthesis. (A-D) The catabolic activities of the indicated T cells were measured by the generation of $^3\text{H}_2\text{O}$ from Glucose, D-[5- ^3H (N)] (A), $^{14}\text{CO}_2$ from D-Glucose, [1- ^{14}C] (B), $^3\text{H}_2\text{O}$ from Palmitic acid, [9,10- ^3H] (C), $^{14}\text{CO}_2$ from [U- ^{14}C]-glutamine (D), n=3, data are representative of 2 independent experiments. n.s., not significant, ** p < 0.01, *** p < 0.001, Student's *t* test. (E) Diagram of [$^{13}\text{C}_5$]-Glutamine catabolism through entering the downstream TCA cycle, aspartate synthesis and pyrimidine biosynthesis. α-KG: α-ketoglutarate; XMP: uridine, cytidine and thymidine monophosphate; SDH: Succinate dehydrogenase; ●: denoted the ^{13}C label of all carbons of indicated metabolites that are derived from [$^{13}\text{C}_5$]-glutamine catabolism. Solid and dashed arrows represent single-

and multi-step reactions (left panel), metabolites were extracted and analyzed using IC-UHR-FTMS (right panel), numbers in the X-axis represent those of ^{13}C atoms in given metabolites, and numbers in the Y-axis represent the levels of the metabolites ($\mu\text{mole/g}$ protein). $n=3$ from one experiment, $*p < 0.05$, $***p < 0.001$, two-way ANOVA. UMP/UDP: uridine mono/diphosphate; dUMP deoxyuridine monophosphate; CMP/CDP: uridine mono/diphosphate; dTMP: deoxythymidine monophosphate; **(F)** The incorporation of carbon from ^{14}C -glutamine into DNA and RNA was determined by the isotope uptake, $n=3$, data are representative of 2 independent experiments. $*p < 0.05$, Student's t test. **(G)** Metabolites of the indicated T cells were determined by CE-QqQ/TOFMS and depicted in the Heatmap. **(H)** DNA and RNA content of the indicated CD4^+ T cells were determined by the 7AAD and pyronin-Y uptake. Bar graphs, mean \pm SEM. T cells were activated by the plate-bound anti-CD3/CD28 antibodies.




Figure 3. Nucleoside supplementation partially compensates for the loss of de novo biosynthesis of nucleotides in SDHB cKO T cells.

(A-D) CD4⁺ T cells were activated for 72 hrs with or without nucleosides (NS: adenosine, guanosine, thymidine, cytidine, uridine and inosine), cell viability was calculated based on the 7AAD staining (A-B), cell number was measured by a cell counter (C), cell proliferation was determined by CFSE dilution (D), n=3, data are representative of 3 independent experiments, ***p* < 0.01, ****p* < 0.001, one-way ANOVA. (E) DNA and RNA content of the indicated T cells (plate-bound anti-CD3/CD28 activation for 36 hrs) were determined by the 7AAD and pyronin staining. (F) The cell cycle profile of the indicated T cells (plate-bound anti-CD3/CD28 activation for 48 hrs) was analyzed by BrdU and 7AAD staining. (G-J)

CD4⁺ T cells were activated for 72 hrs with TCU (thymidine, cytidine and uridine), TCUI (thymidine, cytidine, uridine and inosine), or NS, cell viability was determined by the 7AAD uptake (**G-H**), and cell number was measured by a cell counter (**I**), cell proliferation was determined by CFSE dilution (**J**), n=3, data are representative of 3 independent experiments, * $p < 0.05$, *** $p < 0.001$, one-way ANOVA. Bar graphs, mean \pm SEM. T cells were activated by the plate-bound anti-CD3/CD28 antibodies.




Figure 4. SDHB deficiency promotes a pro-inflammatory gene signature in T cells after activation.

(A-C) Transcriptomic analysis of RNA-seq data in activated CD3⁺ T cells (30h). (A) Volcano plot. The log₂ FC indicates the mean expression level for each gene. Each dot represents one gene. Red dots represent up-regulated genes; black dots represent down-regulated genes; the blue dots indicate presentative genes in the hallmark gene sets. Highlighted genes (A) were selected based on genes of interest. (B) The most up-regulated pathways were identified by ingenuity pathway analysis (IPA). (C) The signature of differentially expressed genes was identified by GSEA. (D) mRNA levels of indicated genes were determined by qPCR, n=3, data are representative of 3 independent experiments, **p* < 0.05, ****p* < 0.001, one-way ANOVA. (E) CD4⁺ T cells were activated for 36 hrs with indicated treatment, mRNA levels of indicated genes were measured by qPCR, n=3, data

are representative of 3 independent experiments, n.s., not significant, *** $p < 0.001$, one-way ANOVA. (F) Cell culture media from the indicated T cell groups (36 hrs after activation) were collected, mixed with fresh medium at 1:1 ratio, and then were used for culturing WT T cells for 36 hrs under activation condition (left panel), mRNA levels of indicated genes were measured by the qPCR (right panel), n=3, data are representative of 2 independent experiments, n.s., not significant, * $p < 0.05$, Student's *t* test. Bar graphs, mean \pm SEM. NS: nucleosides. T cells were activated by the plate-bound anti-CD3/CD28 antibodies.




Figure 5. Increasing the intracellular succinate/ α -KG ratio promotes pro-inflammatory signature in T cells after activation.

(A) Schematic diagram of succinate-mediated metabolic, signaling, and epigenetic regulation of T cell proliferation and inflammation. (B) CD4⁺ T cells were cultured with 100 μ M cell permeable succinate (NV118) followed by activation as indicated in the experimental diagram (top panel), mRNA levels of indicated genes were measured by qPCR (bottom panel, n=3, data are representative of 3 independent experiments, * p < 0.05, ** p < 0.01, *** p < 0.001, student's t test). (C) CD4⁺ T cells were activated for 36 hrs with or without 10mM α -KG, mRNA levels of indicated genes were measured by qPCR, n=3, data are representative of 3 independent experiments, *** p < 0.001, one-way ANOVA.

(D) Schematic diagram of R162's action and glutamine catabolism (left panel), CD4⁺ T cells were activated for 36 hrs with indicated treatments, mRNA levels of indicated genes were measured by the qPCR (right panel), n=3, data are representative of 2 independent experiments, *** $p < 0.001$, one-way ANOVA. T cells (B-D) were activated by the plate-bound anti-CD3/CD28 antibodies. **(E-F)** CD4⁺ T cells were polarized toward T_H1 **(E)** and T_H17 **(F)** lineages for 72 hrs with indicated treatments (2mM α -KG and 25 μ M NV118). The indicated proteins were quantified by intracellular staining by flow cytometry. Cell proliferation was determined by CFSE staining, n=3, data are representative of 3 independent experiments, * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, one-way ANOVA. Bar graphs, mean \pm SEM.




Figure 6. SDHB deficiency increases the level of succinate to enhance DNA accessibility and pro-inflammatory genes transcription.

(A) Differential chromatin accessibility was measured by ATAC-seq in activated CD4⁺ T cells between indicated genotypes (n=3 replicates for each genotype), identifying 8,543 sites with accessibility gain and 1,521 sites with accessibility loss in activated *SDHB* cKO T cells. (B) ATAC-seq peaks with differential accessibility were linked to nearby genes, and ontology analysis was performed using GREAT. (C) Accessibility changes in differential ATAC-seq peaks were plotted against expression changes (CD4⁺ T cells RNA-seq) in the nearby genes identified in (B), concordant changes (i.e., enhanced expression and accessibility) were observed among pro-inflammatory genes and master transcription factors mediating inflammation. (D) Motif analysis was performed on ATAC-seq peaks

showing enhanced accessibility in activated *SDHB* cKO CD4⁺ T cells. A volcano plot shows up-regulated expression of many cognate transcription factors by RNA-seq. Highlighted genes (**C&D**) were selected based on genes of interest. (**E**) mRNA levels of transcription factors in the indicated CD4⁺ T cells were depicted in the Heatmap, (n=3 replicates for each group). (**F**) CD4⁺ T cells were activated for 36 hrs with or without 10mM α -KG, Blimp1 protein levels were measured by intracellular staining by flow cytometry, MFI was analyzed, n=3, data are representative of 3 independent experiments, ** $p < 0.01$, *** $p < 0.001$, one-way ANOVA. (**G**) CD4⁺ T cells were maintained in naïve condition with 100 μ M NV118 for 72 hrs and then activated for 36 h, Blimp1 protein levels were measured by intracellular staining by flow cytometry, MFI was analyzed, n=3, data are representative of 3 independent experiments, ** $p < 0.01$, student's *t* test. Bar graphs, mean \pm SEM. T cells were activated by the plate-bound anti-CD3/CD28 antibodies.




Figure 7. Succinate-mediated *Prdm1*/Blimp1 expression contributes to proinflammatory signature in T cells.

(A) CD4⁺ T cells were activated overnight, then electroporated with *gPrdm1* and Cas9, cells were recovered in culture medium for 2 hrs prior to activation for 40 hrs (top panel), Blimp-1 protein levels were measured by intracellular staining by flow cytometry (bottom panel), n=3, data are representative of 2 independent experiments, ***p* < 0.01, one-way ANOVA. (B) CD4⁺ T cells were electroporated with *gPrdm1* and Cas9, mRNA levels of indicated genes were determined by qPCR, n=3, data are representative of 2 independent experiments, n.s., not significant, ***p* < 0.01, ****p* < 0.001, one-way ANOVA. (C-D) CD4⁺ T cells were activated overnight, then electroporated with *gPrdm1* and Cas9. Cells were then polarized toward T_H1 (C) and T_H17 (D) lineages for 72 hrs with or without 25 μ M NV118. The indicated proteins were quantified by intracellular staining by flow cytometry, cell proliferation was determined by CFSE staining. n=3, data are representative

of 2 independent experiments, $***p < 0.001$, one-way ANOVA. Bar graphs, mean \pm SEM. T cells were activated by the plate-bound anti-CD3/CD28 antibodies.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript